Related Experiment Video
Updated: Sep 5, 2025

Nephrotoxin Microinjection in Zebrafish to Model Acute Kidney Injury
Published on: July 17, 2016
Incidence, patterns, risk factors and clinical outcomes of intravenous acyclovir induced nephrotoxicity
Abdullah M Al-Alawi1,2, Juhaina Salim Al-Maqbali3, Maria Al-Adawi2
1Department of Medicine, Sultan Qaboos University Hospital, Muscat, Oman.
Objectives:
Acyclovir is approved to treat herpes simplex virus (HSV) type 1, type 2 and varicella-zoster virus. It is mainly eliminated via the kidneys, for which drug crystals accumulation might lead to nephrotoxicity. This study aimed to determine the incidence, risk factors, preventive measures, and clinical outcomes of acyclovir induced-nephrotoxicity.
Methods:
This is a retrospective cohort study of patients >12 years of age at Sultan Qaboos University Hospital (SQUH) receiving IV acyclovir therapy between January 2016 and December 2020.
Results:
Out of 191 included patients, 40 (20.1%) developed acyclovir induced-nephrotoxicity. Age (per year older: OR 1.04, 95 %CI 1.01-1.07), total duration of treatment (per day OR1.19, 95 %CI 1.06-1.33), and concomitant use of vancomycin (OR 5.96, 95 %CI 1.87-19.01) were significant independent risk factors for acyclovir induced-nephrotoxicity development. Nine patients (4.5%) died during the same hospitalization, including those three patients who required renal replacement therapy (1.5%).
Conclusion:
Frequent monitoring of kidney function for older patients with concurrent use of vancomycin and IV hydration is essential to prevent IV acyclovir induced-nephrotoxicity. Antimicrobial stewardship is a crucial method to reduce the duration of treatment with IV acyclovir as appropriate.
Insights
Acyclovir-induced nephrotoxicity occurred in 20.1% of patients. Advanced age, longer treatment duration, and vancomycin use increased risk. Kidney function monitoring and IV hydration are crucial for prevention.
Area of Science:
- Pharmacology
- Nephrology
- Infectious Diseases
Background:
- Acyclovir is a key antiviral medication for herpes simplex virus (HSV) and varicella-zoster virus.
- Renal excretion of acyclovir can lead to drug crystal accumulation and potential nephrotoxicity.
- Understanding acyclovir-induced nephrotoxicity is critical for patient safety.
Purpose of the Study:
- To determine the incidence of acyclovir-induced nephrotoxicity.
- To identify significant risk factors associated with its development.
- To outline preventive measures and clinical outcomes.
Main Methods:
- Retrospective cohort study design.
- Inclusion of patients over 12 years old receiving intravenous (IV) acyclovir.
- Data collected from January 2016 to December 2020 at Sultan Qaboos University Hospital.
Main Results:
- Acyclovir-induced nephrotoxicity was observed in 40 out of 191 patients (20.1%).
- Independent risk factors included older age, longer duration of IV acyclovir treatment, and concurrent vancomycin administration.
- Mortality was 4.5%, with 1.5% requiring renal replacement therapy.
Conclusions:
- Close monitoring of renal function is essential for patients receiving IV acyclovir, particularly older individuals and those on vancomycin.
- Intravenous hydration is a key preventive strategy.
- Antimicrobial stewardship programs can help minimize treatment duration, thereby reducing nephrotoxicity risk.
More Related Videos
08:04Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
Published on: July 9, 2014
08:31Porcine Corneal Tissue Explant to Study the Efficacy of Herpes Simplex Virus-1 Antivirals
Published on: September 20, 2021
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury I: Introduction
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury VI: Nursing Management
Acute Kidney Injury V: Interprofessional Care